본문 바로가기
KERD
논문KCI 등재

Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics

김원호|김은수
거트앤리버 소화기연관학회협의회|2010.03|Gut and Liver|제4권 제1호|pp. 1-14

2

조회

0

다운로드

28

인용

0

참고문헌

초록

Inflammatory bowel disease (IBD) describes chronic inflammatory disease of the intestines and has a variable course; Crohn’s disease and ulcerative colitis comprise the two main forms of the condition. Although IBD occurs worldwide, its epidemiologic and clinical characteristics vary depending upon the geographic location and the ethnicity of the population. Identifying the characteristic features of IBD in populations living in different geographical locations and with different ethnicities may provide significant clues about its etiology and pathophysiology, which in turn may be helpful in the development of more appropriate treatment strategies for IBD for these different populations. Therefore, it is important for each country and region to evaluate critically the epidemiology, genomics,and clinical characteristics of IBD among its own population. We have performed a critical review of the recent data in Korea, and describe herein the current epidemiologic and genotypic status, as well as the clinical manifestations and therapeutic responses of IBD that are unique to Korean patients.

Abstract

Inflammatory bowel disease (IBD) describes chronic inflammatory disease of the intestines and has a variable course; Crohn’s disease and ulcerative colitis comprise the two main forms of the condition. Although IBD occurs worldwide, its epidemiologic and clinical characteristics vary depending upon the geographic location and the ethnicity of the population. Identifying the characteristic features of IBD in populations living in different geographical locations and with different ethnicities may provide significant clues about its etiology and pathophysiology, which in turn may be helpful in the development of more appropriate treatment strategies for IBD for these different populations. Therefore, it is important for each country and region to evaluate critically the epidemiology, genomics,and clinical characteristics of IBD among its own population. We have performed a critical review of the recent data in Korea, and describe herein the current epidemiologic and genotypic status, as well as the clinical manifestations and therapeutic responses of IBD that are unique to Korean patients.

참고문헌 (147)

  1. Yang SK, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study", Inflamm Bowel Dis, 14, pp.542~549 (2008)
  2. Leong RW, "The epidemiology and phenotype of Crohn's disease in the Chinese population", Inflamm Bowel Dis, 10, pp.646~651 (2004)
  3. Morita N, "Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991", J Gastroenterol, 30(Suppl. 8), pp.1~4 (1995)
  4. Yang SK, "Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997", J Gastroenterol Hepatol, 15, pp.1037~1042 (2000)
  5. Ling KL, "Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state", J Clin Gastroenterol, 35, pp.144~148 (2002)
  6. Iida M, "Long-term follow-up study of Crohn's disease in Japan: the Research Committee of Inflammatory Bowel Disease in Japan", J Gastroenterol, 30(Suppl. 8), pp.17~19 (1995)
  7. Inoue N, "Lack of common NOD2 variants in Japanese patients with Crohn's disease", Gastroenterology, 123, pp.86~91 (2002)
  8. Yang SK, "Epidemiology of inflammatory bowel disease in Asia", Inflamm Bowel Dis, 7, pp.260~270 (2001)
  9. Kim BJ, "Trends of ulcerative colitis-associated colorectal cancer in Korea: a KASID study", J Gastroenterol Hepatol, 24, pp.667~671 (2009)
  10. 장동경, "한국인의 궤양성 대장염 연관 대장암의 현황: 대한장연구학회 다기관 공동연구", 대한소화기학회지, 46(4), pp.276~282 (2005), 대한소화기학회
  11. Cheon JH, "Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases", Hepatogastroenterology, 56, pp.421~423 (2009)
  12. Lee SK, "Differential diagnosis of intestinal Behcet's disease and Crohn's disease by colonoscopic findings", Endoscopy, 41, pp.9~16 (2009)
  13. Kim JY, "The incidence and natural history of perianal fistulas in Korean patients with Crohn's disease", Intest Res, 4, pp.22~31 (2006)
  14. Ko YT, "Twenty cases of restorative proctocolectomy for ulcerative colitis of Asian patients: analysis of operative safety and functional outcomes in single institution experience", Int J Colorectal Dis, 23, pp.131~132 (2008)
  15. 이진혁, "한국인 크론병 환자에서 NOD2 유전자 돌연변이의 빈도분석", 대한소화기학회지, 45(3), pp.162~168 (2005), 대한소화기학회
  16. Lee H, "Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease", Dig Liver Dis, 38, pp.659~664 (2006)
  17. Lee JH, "The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis", Dig Dis Sci. Forthcoming, 55(5) (2010)
  18. Lee YJ, "Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease", Endoscopy, 38, pp.592~597 (2006)
  19. Park JJ, "Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease", Dig Dis Sci, 54, pp.1525~1531 (2009)
  20. Park SH, "Clinical features and natural history of ulcerative colitis in Korea", Inflamm Bowel Dis, 13, pp.278~283 (2007)
  21. Russel MG, "Changes in the incidence of inflammatory bowel disease: what does it mean?", Eur J Intern Med, 11, pp.191~196 (2000)
  22. Cashman KD, "Is nutrition an aetiological factor for inflammatory bowel disease?", J Gastroenterol Hepatol, 15, pp.607~613 (2003)
  23. Jovanovic Z, "Epidemiology of Crohn's disease in the Rijeka-Istra region", Lijec Vjesn, 121, pp.8~13 (1999)
  24. Appleyard CB, "Basic epidemiology of inflammatory bowel disease in Puerto Rico", Inflamm Bowel Dis, 10, pp.106~111 (2004)
  25. Linares de la Cal JA, "Estimated incidence of inflammatory bowel disease in Argentina and Panama (1987-1993)", Rev Esp Enferm Dig, 91, pp.277~286 (1999)
  26. Lakatos L, "Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001", World J Gastroenterol, 10, pp.404~409 (2004)
  27. Sincic BM, "Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000-2004: a prospective population-based study", Scand J Gastroenterol, 41, pp.437~444 (2006)
  28. Molinie F, "Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999)", Gut, 53, pp.843~848 (2004)
  29. Lapidus A, "Crohn's disease in Stockholm County during 1990-2001: an epidemiological update", World J Gastroenterol, 12, pp.75~81 (2006)
  30. Loftus EV Jr, "Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival", Gastroenterology, 114, pp.1161~1168 (1998)
  31. Loftus EV Jr, "Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival", Gut, 46, pp.336~343 (2000)
  32. Bernstein CN, "The epidemiology of inflammatory bowel disease in Canada: a population-based study", Am J Gastroenterol, 101, pp.1559~1568 (2006)
  33. Gearry RB, "High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study", Inflamm Bowel Dis, 12, pp.936~943 (2006)
  34. Yao T, "Crohn's disease in Japan: diagnostic criteria and epidemiology", Dis Colon Rectum, 43(Suppl. 10), pp.S85~S93 (2000)
  35. Sands BE, "From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation", Gastroenterology, 126, pp.1518~1532 (2004)
  36. 박종범, "한국인 크론병의 진단시 임상 양상과 경과", 대한소화기학회지, 43(1), pp.8~17 (2004), 대한소화기학회
  37. Calkins BM, "Trends in incidence rates of ulcerative colitis and Crohn's disease", Dig Dis Sci, 29, pp.913~920 (1984)
  38. Lennard-Jones JE, "Classification of inflammatory bowel disease", Scand J Gastroenterol Suppl, 170, pp.2~6 (1989)
  39. Myren J, "The OMGE multinational inflammatory bowel disease survey 1976-1986: a further report on 3175 cases", Scand J Gastroenterol Suppl, 144, pp.11~19 (1988)
  40. Saxon A, "A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease", J Allergy Clin Immunol, 86, pp.202~210 (1990)
  41. Vermeire S, "Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease", Gastroenterology, 120, pp.827~833 (2001)
  42. Kim BG, "Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease", Dis Colon Rectum, 45, pp.1062~1069 (2002)
  43. Hugot JP, "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease", Nature, 41, pp.599~603 (2001)
  44. Ogura Y, "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease", Nature, 411, pp.603~606 (2001)
  45. Hampe J, "Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations", Lancet, 357, pp.1925~1928 (2001)
  46. Stoll M, "Genetic variation in DLG5 is associated with inflammatory bowel disease", Nat Genet, 36, pp.476~480 (2004)
  47. Till A, "The Met-196 → Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression", J Biol Chem, 280, pp.5994~6004 (2005)
  48. Duerr RH, "A genome-wide association study identifies IL23R as an inflammatory bowel disease gene", Science, 314, pp.1461~1463 (2006)
  49. Hampe J, "A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1", Nat Genet, 39, pp.207~211 (2007)
  50. Rioux JD, "Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis", Nat Genet, 39, pp.596~604 (2007)
  51. Parkes M, "Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility", Nat Genet, 39, pp.830~832 (2007)
  52. Raelson JV, "Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci", Proc Natl Acad Sci USA, 104, pp.14747~14752 (2007)
  53. Riis L, "The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients", Inflamm Bowel Dis, 13, pp.24~32 (2007)
  54. Targan SR, "Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease", Gastroenterology, 128, pp.2020~2028 (2005)
  55. Braun J, "Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease", Adv Exp Med Biol, 579, pp.209~218 (2006)
  56. Nikolaus S, "Diagnostics of inflammatory bowel disease", Gastroenterology, 133, pp.1670~1689 (2007)
  57. Oriuchi T, "Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality", J Gastroenterol, 38, pp.942~953 (2003)
  58. Vind I, "Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a populationbased study from the Danish Crohn colitis database", Am J Gastroenterol, 101, pp.1274~1282 (2006)
  59. Croucher PJ, "Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations", Eur J Hum Genet, 11, pp.6~16 (2003)
  60. Yang SK, "Association of TNF-alpha", LTA polymorphisms with Crohn's disease in Koreans, 2006, pp.35, 13~20
  61. Yang SK, "Association of TNFSF15 with Crohn's disease in Koreans", Am J Gastroenterol, 103, pp.1437~1442 (2008)
  62. Yang SK, "Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans", Inflamm Bowel Dis, 15, pp.1385~1390 (2009)
  63. Yoshitake S, "HLA class II alleles in Japanese patients with inflammatory bowel disease", Tissue Antigens, 53, pp.350~358 (1999)
  64. Masuda H, "Distinct relationship between HLA-DR genes and intractability of ulcerative colitis", Am J Gastroenterol, 89, pp.1957~1962 (1994)
  65. Myung SJ, "HLA-DRB1*1502 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: a Korean study", Int J Colorectal Dis, 17, pp.233~237 (2002)
  66. Satsangi J, "Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease", Lancet, 347, pp.1212~1217 (1996)
  67. De La Concha EG, "Positive and negative associations of distinct HLA-DR2 subtypes with ulcerative colitis (UC)", Clin Exp Immunol, 108, pp.392~395 (1997)
  68. Cottone M, "Ulcerative colitis and HLA phenotype", Gut, 26, pp.952~954 (1985)
  69. Truelove SC, "Cortisone in ulcerative colitis; final report on a therapeutic trial", Br Med J, 2, pp.1041~1048 (1955)
  70. Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study", N Engl J Med, 317, pp.1625~1629 (1987)
  71. Shivananda S, "Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)", Gut, 39, pp.690~697 (1996)
  72. Modigliani R, "Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives", Gastroenterology, 98, pp.811~818 (1990)
  73. Fiocchi C, "Inflammatory bowel disease: etiology and pathogenesis", Gastroenterology, 115, pp.182~205 (1998)
  74. Gasche C, "A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998", Inflamm Bowel Dis, 6, pp.8~15 (2000)
  75. Louis E, "Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease", Gut, 49, pp.777~782 (2001)
  76. Satsangi J, "The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
  77. Han JY, "Clinical outcome of Crohn's disease", Korean J Gastroenterol, 40(Suppl 5), pp.187A~ (2002)
  78. Best WR, "Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)", Gastroenterology, 77, pp.843~846 (1979)
  79. Sandborn WJ, "A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease", Gastroenterology, 122, pp.512~530 (2002)
  80. Harvey RF, "A simple index of Crohn's-disease activity", Lancet, 1, pp.514~ (1980)
  81. Van Hees PA, "Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study", Gut, 22, pp.404~409 (1981)
  82. Anthonisen P, "The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study", Scand J Gastroenterol, 9, pp.549~554 (1974)
  83. Summers RW, "National Cooperative Crohn's Disease Study: results of drug treatment", Gastroenterology, 77, pp.847~869 (1979)
  84. Malchow H, "European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment", Gastroenterology, 86, pp.249~266 (1984)
  85. Tremaine WJ, "A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis", J Clin Gastroenterol, 19, pp.278~282 (1994)
  86. Singleton JW, "Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group", Gastroenterology, 104, pp.1293~1301 (1993)
  87. Hanauer SB, "Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials", Clin Gastroenterol Hepatol, 2, pp.379~388 (2004)
  88. Sutherland L, "Double blind, placebo controlled trial of metronidazole in Crohn's disease", Gut, 32, pp.1071~1075 (1991)
  89. Ambrose NS, "Antibiotic therapy for treatment in relapse of intestinal Crohn's disease: a prospective randomized study", Dis Colon Rectum, 28, pp.81~85 (1985)
  90. Blichfeldt P, "Metronidazole in Crohn's disease: a double blind cross-over clinical trial", Scand J Gastroenterol, 13, pp.123~127 (1978)
  91. Steinhart AH, "Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial", Gastroenterology, 123, pp.33~40 (2002)
  92. Greenberg GR, "Oral budesonide for active Crohn's disease: Canadian Inflammatory Bowel Disease Study Group", N Engl J Med, 331, pp.836~841 (1994)
  93. Tremaine WJ, "Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States", Am J Gastroenterol, 97, pp.1748~1754 (2002)
  94. Kane SV, "The effectiveness of budesonide therapy for Crohn's disease", Aliment Pharmacol Ther, 16, pp.1509~1517 (2002)
  95. Lichtenstein GR, "American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease", Gastroenterology, 130, pp.935~939 (2006)
  96. Travis SP, "European evidence based consensus on the diagnosis and management of Crohn's disease: current management", Gut, 55(Suppl 1), pp.i16~i35 (2006)
  97. Hyun JG, "Analysis of clinical, biochemical and pathologic factors according to the response to initial steroid therapy in active Crohn's disease", Korean J Gastrointest Endosc, 22, pp.406~410 (2001)
  98. Kim DH, "Response rate to oral steroid therapy in patients with Crohn's disease and its clinical predictive factors", 석사, pp.2009
  99. Lee KM, "Infliximab treatment in Crohn's disease: a nation-wide survey in Korea", The 3rd Japan-Korea IBD symposium (2008)
  100. "Health Insurance Review and Assessment Service"[URL]
  101. 안효석, "염증성 장질환 환자에서 수술 후 감염", 대한소화기학회지, 48(5), pp.306~312 (2006), 대한소화기학회
  102. Sandborn WJ, "Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis offour randomized, double-blind, placebo-controlled trials", Am J Gastroenterol, 100, pp.1780~1787 (2005)
  103. Present DH, "Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized, double-blind study", N Engl J Med, 302, pp.981~987 (1980)
  104. Hanauer SB, "Management of Crohn's disease in adults", Am J Gastroenterol, 96, pp.635~643 (2001)
  105. Candy S, "A controlled double blind study of azathioprine in the management of Crohn's disease", Gut, 37, pp.674~678 (1995)
  106. Lemann M, "A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine", Gastroenterology, 128, pp.1812~1818 (2005)
  107. Gearry RB, "Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease", J Gastroenterol Hepatol, 20, pp.1149~1157 (2005)
  108. 김재학, "염증성 장질환 환자에서 Azathioprine", 6-Mercaptopurine 치료의 부작용: 빈도와 경과, 2008, pp.51(5), 291~297[DOI]
  109. Jun JB, "Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine", Clin Exp Rheumatol, 23, pp.873~876 (2005)
  110. Baumgart DC, "Inflammatory bowel disease: clinical aspects and established and evolving therapies", Lancet, 369, pp.1641~1657 (2007)
  111. Smolen JS, "New therapies for treatment of rheumatoid arthritis", Lancet, 370, pp.1861~1874 (2007)
  112. Olaussen RW, "Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation", Gastroenterology, 132, pp.2371~2382 (2007)
  113. Salmi M, "Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans", Blood, 108, pp.1555~1561 (2006)
  114. Silverman J, "Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains", Nat Biotechnol, 23, pp.1556~1561 (2005)
  115. Carter MJ, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 53(Suppl 5), pp.V1~V16 (2004)
  116. Sandborn WJ, "AGA technical review on perianal Crohn's disease", Gastroenterology, 125, pp.1508~1530 (2003)
  117. Hurst RD, "Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected byCrohn's disease", Surgery, 122, pp.661~667 (1997)
  118. Michelassi F, "Surgical management of Crohn'sdisease", Adv Surg, 26, pp.307~322 (1993)
  119. Prantera C, "Indications for surgery in Crohn's disease", Am J Gastroenterol, 85, pp.900~901 (1990)
  120. Broe PJ, "Crohn's disease: are enteroenteral fistulas an indication for surgery?", Surgery, 91, pp.249~253 (1982)
  121. Ribeiro MB, "Intra-abdominal abscess in regional enteritis", Ann Surg, 213, pp.32~36 (1991)
  122. Gardiner KR, "Operative management of small bowel Crohn's disease", Surg Clin North Am, 87, pp.587~610 (2007)
  123. 김덕환, "크론병과 연관된 복강 내 농양에서 비수술 치료의 효용성", 대한소화기학회지, 53(1), pp.29~35 (2009), 대한소화기학회
  124. Bernell O, "Risk factors for surgery and postoperative recurrence in Crohn's disease", Ann Surg, 231, pp.38~45 (2000)
  125. 송인성, "한국에서의 크론병의 임상상", 대한소화기학회지, 40(3) (2002), 대한소화기학회
  126. 김현아, "수술적 치료를 받은 크론병 환자의 임상양상", 대한외과학회지, 69(2), pp.135~138 (2005), 대한외과학회
  127. Cohen RD, "A meta-analysis and overview of the literature on treatmentoptions for left-sided ulcerative colitis and ulcerative proctitis", Am J Gastroenterol, 95, pp.1263~1276 (2000)
  128. Stein RB, "Medical therapy for inflammatory bowel disease", Gastroenterol Clin North Am, 28, pp.297~321 (1999)
  129. Campieri M, "Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas", Lancet, 2, pp.270~271 (1981)
  130. Marshall JK, "Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis", Gut, 40, pp.775~781 (1997)
  131. Safdi M, "A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis", Am J Gastroenterol, 92, pp.1867~1871 (1997)
  132. Faubion WA Jr, "The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study", Gastroenterology, 121, pp.255~260 (2001)
  133. Lee DH, "Experience of cyclosporine A therapy in severe ulcerative colitis refractory to steroid treatment", Korean J Gastroenterol, 30, pp.58~65 (1997)
  134. 정고은, "스테로이드 저항 중증 궤양성 대장염 환자에서 스테로이드와 Cyclosporin A의 병합 투여와 스테로이드 단독 연장 투여의 치료 효과 비교", 대한소화기학회지, 48(4), pp.263~268 (2006), 대한소화기학회
  135. Hanauer S, "Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis", Am J Gastroenterol, 95, pp.1749~1754 (2000)
  136. d'Albasio G, "Maintenance treatment of ulcerative proctitis with mesalazine supposi tories: a double-blind placebo-controlled trial. The Italian IBD Study Group", Am J Gastroenterol, 93, pp.799~803 (1998)
  137. Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)
  138. Berger M, "Growth retardation in children with ulcerative colitis: the effect of medical and surgical therapy", Pediatrics, 55, pp.459~467 (1975)
  139. Gumaste V, "Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis", Gut, 33, pp.938~941 (1992)
  140. Cohen JL, "Practice parameters for the surgical treatment of ulcerative colitis", Dis Colon Rectum, 48, pp.1997~2009 (2005)
  141. 박인자, "대장직장절제술 및 회장낭형성술 후 회장낭염의 발생양상 및 빈도", 대한소화기학회지, 46(2), pp.99~104 (2005), 대한소화기학회
  142. Moum B, "Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease: results of a large, prospective population-based study in southeastern Norway, 1990-93", Scand J Gastroenterol, 32, pp.1005~1012 (1997)
  143. Leijonmarck CE, "Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study", Gut, 31, pp.329~333 (1990)
  144. Langholz E, "Course of ulcerative colitis: analysis of changes in disease activity over years", Gastroenterology, 107, pp.3~11 (1994)
  145. Sinclair TS, "Nonspecific proctocolitis in northeastern Scotland: a community study", Gastroenterology, 85, pp.1~11 (1983)
  146. Farmer RG, "Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients", Dig Dis Sci, 38, pp.1137~1146 (1993)
  147. Hendriksen C, "Long term prognosis in ulcerative colitis: based on results from a regional patient group from the county of Copenhagen", Gut, 26, pp.158~163 (1985)

관련 논문AI추천

Inflammatory bowel disease in Korea: epidemiology and pathophysiology은창수, Jung Won Lee대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제5호What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?윤진영, 차재명, Park Su Bee거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제5호Incidence and Prevalence of Inflammatory Bowel Disease across Asia박지혜, 천재희연세대학교의과대학 · Yonsei Medical Journal2021 · 제62권 제2호소아기에 발병하는 염증성장질환(IBD)은 성인 IBD와 다른 질환인가? - 조기발병 소아 IBD의 역학적, 임상적, 유전학적 특성 및 치료 시 고려 사항-서정기대한소아소화기영양학회 · Pediatric Gastroenterology, Hepatology & Nutrition2011 · 제14권 제1호한국인에서 궤양성 대장염은 증가하는가?양동훈, 양석균대한내과학회 · 대한내과학회지2009 · 제76권 제6호Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data김영호, 김은란, 박동일, 석정윤, 이강문, 이창균, 최성연, 허규찬, Hyeon Ah Lee거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제6호

이 간행물의 다른 논문 (24건)

Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines유병철, 최문석pp. 15-24A Matched Case-Control Study of a Novel Acid-Pump Antagonist and Proton-Pump Inhibitor for the Treatment of Iatrogenic Ulcers Caused by Endoscopic Submucosal Dissection김태년, 장병익, 김용길pp. 25-30Learning Curves for Colonoscopy: A Prospective Evaluation of Gastroenterology Fellows at a Single CenterJung Hun Lee, Kyung Phil Kang, Jong Chun Na, Yeon Mu Chung, Ji Yeon Won, Tek Man Nam, 김나영, 이상협, 이광호, 박영수, 이동훈, 이동호, 김진욱, 황진혁, Eun Sil Lee, 정숙향, Hyun Chul Choi, 정재일, Min Sik Umpp. 31-35The Frequency and Risk Factors of Colorectal Adenoma in Health-Check-up Subjects in South Korea: Relationship to Abdominal Obesity and AgeHyun Woong Lee, 차봉기, 김기승, Hong Ju Moon, Eun Kyung Baek, Seung Young Lee, 김형준, 최창환, 장세경, 도재혁pp. 36-42Suppressed Gastric Mucosal TGF-β1 Increases Susceptibility to H. pylori-Induced Gastric Inflammation and Ulceration: A Stupid Host Defense Response김주현, Seong-Jin Kim, 조윤정, Shin Tae Kim, 김윤재, 한상욱, 함기백pp. 43-53
원문 보기